

Study of Vaccine Efficacy in Health Care Workers (PSVEHCW)

First published: 04/03/2021

Last updated: 25/04/2024

Study

Planned

Administrative details

EU PAS number

EUPAS39736

Study ID

39737

DARWIN EU® study

No

Study countries

-  Albania
-  Belgium
-  France
-  Lithuania
-  Portugal
-  Romania

Study description

Study of efficacy of COVID-19 vaccination in Healthcare workers in Scotland conducted using linked routine healthcare data.

Study status

Planned

Research institutions and networks

Institutions

Public Health Scotland

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

David McAllister david.mcallister@phs.scot

Study contact

david.mcallister@phs.scot

Primary lead investigator

David McAllister

Study timelines

Date when funding contract was signed

Planned: 02/03/2020

Study start date

Planned: 02/03/2020

Date of final study report

Planned: 31/12/2021

Sources of funding

- Other

More details on funding

Public sector body

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Other study registration identification numbers and links

https://github.com/dmcalli2/hcw_vax

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Main study objective:

1. To determine the real-world efficacy of COVID-19 vaccination in HCWs. 2. To determine the effect of vaccinating HCWs on the risk of COVID-19 in individuals with whom they share a household as such an effect would be consistent with an effect of vaccination on transmission

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medical condition to be studied

SARS-CoV-2 test positive

COVID-19 immunisation

Population studied

Age groups

- Children (2 to < 12 years)
 - Adolescents (12 to < 18 years)
 - Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Special population of interest

Renal impaired

Hepatic impaired

Immunocompromised

Pregnant women

Estimated number of subjects

300000

Study design details

Outcomes

Any case of COVID-19 defined as the first positive test for SARS-CoV-2.

Hospitalisation with COVID-19 Severe COVID-19, ie COVID-19 resulting in ICU admission or death

Data analysis plan

Extended cox-models to estimate the hazard ratio for vaccination, treating vaccination as a time-varying covariate.

Documents

Study publications

[Shah A S V, Wood R, Gribben C, Caldwell D, Bishop J, Weir A et al. Risk of hosp...](#)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No